HC Wainwright Begins Coverage on Immunic (NASDAQ:IMUX)

Analysts at HC Wainwright initiated coverage on shares of Immunic (NASDAQ:IMUX - Get Free Report) in a note issued to investors on Monday, Marketbeat Ratings reports. The firm set a "buy" rating and a $10.00 price target on the stock.

Several other research analysts also recently issued reports on the stock. B. Riley started coverage on shares of Immunic in a research note on Tuesday, August 27th. They issued a "buy" rating and a $6.00 target price on the stock. StockNews.com downgraded Immunic from a "hold" rating to a "sell" rating in a research report on Monday, November 11th. Leerink Partnrs upgraded Immunic to a "strong-buy" rating in a research note on Monday, September 9th. Leerink Partners reissued an "outperform" rating and issued a $5.00 target price on shares of Immunic in a report on Monday, September 9th. Finally, EF Hutton Acquisition Co. I raised Immunic to a "strong-buy" rating in a research note on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Immunic currently has an average rating of "Buy" and an average price target of $11.80.

Immunic Trading Up 7.3 %

NASDAQ IMUX traded up $0.08 during trading on Monday, hitting $1.18. The company had a trading volume of 1,375,721 shares, compared to its average volume of 623,524. The company's fifty day moving average is $1.40 and its 200-day moving average is $1.34. The company has a market cap of $106.29 million, a price-to-earnings ratio of -0.99 and a beta of 1.88. Immunic has a one year low of $0.97 and a one year high of $2.11.

Insider Buying and Selling

In related news, Director Richard Alan Rudick bought 87,300 shares of the company's stock in a transaction on Tuesday, November 12th. The shares were bought at an average price of $1.15 per share, with a total value of $100,395.00. Following the transaction, the director now owns 87,300 shares in the company, valued at approximately $100,395. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Immunic

A number of institutional investors and hedge funds have recently modified their holdings of IMUX. Virtu Financial LLC purchased a new position in shares of Immunic during the third quarter worth $50,000. Jane Street Group LLC grew its holdings in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after acquiring an additional 38,553 shares during the period. State Street Corp raised its position in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company's stock valued at $276,000 after acquiring an additional 11,642 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock worth $169,000 after purchasing an additional 42,383 shares in the last quarter. Finally, Ikarian Capital LLC grew its stake in shares of Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company's stock worth $2,128,000 after purchasing an additional 1,162,378 shares during the period. Institutional investors and hedge funds own 51.82% of the company's stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.